Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Counterfeiting Bill Would Give FDA Recall Authority, Boost Funding

Executive Summary

FDA would receive authority to recall products it believes pose a health risk under a bill introduced by Rep. Steve Israel (D-N.Y.)

You may also be interested in...



Anti-Counterfeiting Interim Step Should Be Paper Pedigree, PhRMA Says

Drug products should contain paper pedigrees as an interim anti-counterfeit measure, the Pharmaceutical Research & Manufacturers of America said at FDA's Oct. 15 Anti-Counterfeit Drug Initiative public meeting in Bethesda, Md

Anti-Counterfeiting Interim Step Should Be Paper Pedigree, PhRMA Says

Drug products should contain paper pedigrees as an interim anti-counterfeit measure, the Pharmaceutical Research & Manufacturers of America said at FDA's Oct. 15 Anti-Counterfeit Drug Initiative public meeting in Bethesda, Md

FDA Counterfeiting Task Force To Look At Tighter Wholesaler Licensing

An FDA task force could look to Florida's new drug wholesaler licensing requirements as a model that all states should adopt to combat counterfeiting

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel